APA (7th ed.) Citation

A, M., C, V., P, A., P, L., I, V., & JJ, A. (2025). Anifrolumab as maintenance therapy in a patient with haemophagocytic lymphohistiocytosis secondary to systemic lupus erythematosus. Clinical and experimental rheumatology, 43(3), 547. https://doi.org/10.55563/clinexprheumatol/xmgjcl

Chicago Style (17th ed.) Citation

A, Mayo-Juanatey, Valera-Ribera C, Andújar-Brazal P, León-Torralba P, Vázquez-Gómez I, and Alegre-Sancho JJ. "Anifrolumab as Maintenance Therapy in a Patient with Haemophagocytic Lymphohistiocytosis Secondary to Systemic Lupus Erythematosus." Clinical and Experimental Rheumatology 43, no. 3 (2025): 547. https://doi.org/10.55563/clinexprheumatol/xmgjcl.

MLA (9th ed.) Citation

A, Mayo-Juanatey, et al. "Anifrolumab as Maintenance Therapy in a Patient with Haemophagocytic Lymphohistiocytosis Secondary to Systemic Lupus Erythematosus." Clinical and Experimental Rheumatology, vol. 43, no. 3, 2025, p. 547, https://doi.org/10.55563/clinexprheumatol/xmgjcl.